Revenues grew 14% reaching $1.779M in Q2/26, beating management projections Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from ‘WGRX' to ‘MEDS' on NASDAQ Capital Markets $6.5 million new funding in June 2026 provided capital to support corporate turnaround Pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate patent protected blockchain, biometrics and pharmaceutical-adjunct products intellectual properties to deliver the "Health Lives Here" consumer app, in partnership with NFL Alumni Health (NFLAH), to deliver an effective healthcare experience to patients in rural communities via local independent pharmacies 1:50 reverse split in May 2026 implemented to partially address NASDAQ delisting risk Holders of 1,533,930 common shares, representing ~49% of shares outstanding, have entered into lock-up agreements for at least an additional ninety (90) days Dream Bowl Meme Coin I token distribution Payment Date set as September 9, 2026 with ratio of 50 tokens per common share owned as of end of business August 7, 2026 KareRx joint venture added Electronic Benefits Verification (EBV) and access to 200,000 patient lives that began to provide material revenue to rebranded Corexa Pharmacy Neuritek Therapeutics, Inc. pending acquisition was terminated in May 2026 TAMPA, FL / ACCESS Newswire / August 17, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today reported second quarter 2026 financials and provided a business update. The Company is expecting to launch the Health Lives Here (HLH) consumer app together with National Football League Alumni Health (NFLAH) in September 2026, targeting patients on or contemplating taking GLP-1 agonist medications in rural communities through their local independent pharmacies.